文献速递糖尿病

吡格列酮改善糖尿病患者左心室舒张功能

Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes.
PubMed 文献 · Diabetes Care · 2017-08-28

研究纳入12例2型糖尿病和12例糖耐量正常者,接受高胰岛素-正葡萄糖钳夹及正电子发射断层扫描和磁共振成像,评估吡格列酮治疗24周前后心肌胰岛素敏感性和左心室功能。结果显示吡格列酮降低HbA1c 0.9%,降低收缩压和舒张压各7±2 mmHg,增加全身胰岛素刺激的葡萄糖摄取71%、心肌葡萄糖摄取75%、心肌灌注16%,并改善舒张功能E/A比值和峰值左心室充盈率。结论认为吡格列酮改善2型糖尿病患者的全身及心肌胰岛素敏感性、左心室舒张功能和收缩功能。

要点

  • 吡格列酮治疗24周降低2型糖尿病患者HbA1c 0.9%,降低收缩压和舒张压各7±2 mmHg。
  • 吡格列酮增加全身胰岛素刺激的葡萄糖摄取71%、心肌葡萄糖摄取75%、心肌灌注16%。
  • 吡格列酮改善左心室舒张功能(E/A比值和峰值充盈率)及收缩功能(射血分数和每搏量)。

核心结论

  • 吡格列酮改善2型糖尿病患者的全身及心肌胰岛素敏感性、左心室舒张功能和收缩功能,且心肌胰岛素敏感性改善与舒张功能改善强相关。

研究设计与样本

  • 研究纳入12例2型糖尿病受试者和12例糖耐量正常受试者,接受高胰岛素-正葡萄糖钳夹。
  • 采用[18F]氟代脱氧葡萄糖和[15O]水正电子发射断层扫描测量心肌葡萄糖摄取和心肌灌注,采用磁共振成像测量心肌功能和经二尖瓣早期舒张/心房收缩(E/A)血流比值。
  • 在吡格列酮治疗24周前后进行上述测量。

主要发现

  • 在2型糖尿病受试者中,吡格列酮降低HbA1c 0.9%,降低收缩压和舒张压各7±2 mmHg(P<0.05),增加全身胰岛素刺激的葡萄糖摄取71%(3.4±1.3至5.8±2.1 mg/kg·min;P<0.01)。
  • 吡格列酮增加心肌葡萄糖摄取75%(0.24±0.14至0.42±0.13 μmol/min·g;P<0.01)和心肌灌注16%(0.95±0.16至1.10±0.25 mL/min·g;P<0.05)。
  • 舒张功能指标E/A比值(1.04±0.3至1.25±0.4)和峰值左心室充盈率(349±107至433±99 mL/min)均增加(P<0.01)。
  • 收缩末期容积、舒张末期容积、峰值左心室射血率和心输出量呈增加趋势(P无显著性),而射血分数(61±6至66±7%)和每搏量(71±20至80±20 L/min)显著增加(两者P<0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the effect of pioglitazone on myocardial insulin sensitivity and left ventricular (LV) function in patients with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: Twelve subjects with T2D and 12 with normal glucose tolerance received a euglycemic insulin clamp. Myocardial glucose uptake (MGU) and myocardial perfusion were measured with [18F]fluoro-2-deoxy-d-glucose and [15O]H2O positron emission tomography before and after 24 weeks of pioglitazone treatment. Myocardial function and transmitral early diastolic relation/atrial contraction (E/A) flow ratio were measured with magnetic resonance imaging. RESULTS: Pioglitazone reduced HbA1c by 0.9%; decreased systolic and diastolic blood pressure by 7 ± 2 and 7 ± 2 mmHg, respectively (P < 0.05); and increased whole-body insulin-stimulated glucose uptake by 71% (3.4 ± 1.3 to 5.8 ± 2.1 mg/kg · min; P < 0.01) in subjects with T2D. Pioglitazone enhanced MGU by 75% (0.24 ± 0.14 to 0.42 ± 0.13 μmol/min · g; P < 0.01) and myocardial perfusion by 16% (0.95 ± 0.16 to 1.10 ± 0.25 mL/min · g; P < 0.05). Measures of diastolic function, E/A ratio (1.04 ± 0.3 to 1.25 ± 0.4) and peak LV filling rate (349 ± 107 to 433 ± 99 mL/min), both increased (P < 0.01). End-systolic volume, end-diastolic volume, peak LV ejection rate, and cardiac output trended to increase (P not significant), whereas the ejection fraction (61 ± 6 to 66 ± 7%) and stroke volume increased significantly (71 ± 20 to 80 ± 20 L/min; both P < 0.05). CONCLUSIONS: Pioglitazone improves whole-body and myocardial insulin sensitivity, LV diastolic function, and systolic function in T2D. Improved myocardial insulin sensitivity and diastolic function are strongly correlated.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Clarke GD, Solis-Herrera C, Molina-Wilkins M, et al. Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes. Diabetes Care. 2017. PMID: 28847910. doi:10.2337/dc17-0078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。